UNIVERSITY OF VIENNA, Vienna, Austria
T18 - Exploiting Physical Organic Principles in Reaction Design
UNIVERSITY OF MÜNSTER, Münster, Germany
Ryan Gilmour (b. 1980) was born in Ayrshire, Scotland, and educated at the universities of St Andrews and Cambridge (Ph.D. with Prof. A. B. Holmes FRS). After post-doctoral stays at the Max-Planck-Institut für Kohlenforschung (Prof. A. Fürstner) and the ETH Zürich (Prof. P. H. Seeberger) he was awarded the Alfred-Werner-Assistant-Professorship. Between 2008 and 2013 he was an assistant professor of organic chemistry at the ETH Zürich. In 2013 he moved to the Westfälische Wilhelms-Universität Münster where he is full professor of organic chemistry and chemical biology.
T19 - Automation, Integration and Miniaturization In Drug Discovery Synthesis
NOVARTIS PHARMA AG, Schlieren, Switzerland
Dr. Guido Koch, Director in Global Discovery Chemistry is responsible for strategies and technologies in synthesis. His focus is to enable challenging chemistry and apply innovative synthesis design for fast and high quality lead optimization in collaboration with Medicinal Chemistry teams. In addition the group evaluates, develops and implements new technologies in synthesis. He is member of the Global Discovery Chemistry leadership team.
During his career at Novartis in different functions, Guido has contributed to drug discovery and development in different phases starting from target ID up to early clinical trials in man. In addition, Guido has been responsible for building and maintaining the Global Discovery Chemistry University relations network in Europe.
Guido received his Diploma in Chemistry and Biochemistry from ETH Zürich in 1991 and a PhD in Chemistry from the University of Basel in 1996. After a postdoc at California Institute of Technology he joined Novartis in 1997 in Process R&D before moving into drug discovery chemistry in 2001.
OC08 - Exploring New Methods for Facile Synthesis of Some Biologically Interesting Molecules
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai, China
Ming-Hua Xu was born in Zhejiang, China. He obtained his Ph.D. from Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences in 1999. Following postdoctoral research at the University of Virginia and Georgetown University Medical Center, he joined the faculty at SIOC as an associate professor in 2003. He has been a professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences since 2005. He is the recipient of the Chinese Chemical Society Award for Young Chemist (2005), CAS Hundred Talent Program (2005), WuXi PharmaTech Life Science & Chemistry Award (2007), National Science Fund for Distinguished Young Scholar (2013), CAS Excellent Mentor Award (2013), Shanghai Academic Research Leader (2014), Shanghai Natural Science Award (1st prize, 2014) and National Natural Science Award (2nd prize, 2016). His research interests mainly involve asymmetric synthesis and drug discovery.
Coffee Break and Exhibition
T20 - Design and Evolution of New Biocatalysts for Organic Synthesis
Nicholas John TURNER
UNIVERSITY OF MANCHESTER, Manchester, United Kingdom
Nick Turner obtained his DPhil in 1985 with Professor Sir Jack Baldwin and from 1985-1987 was a Royal Society Junior Research Fellow, spending time at Harvard University with Professor George Whitesides. He was appointed lecturer in 1987 at Exeter University and moved to Edinburgh in 1995, initially as a Reader and subsequently Professor in 1998. In October 2004 he joined Manchester University as Professor of Chemical Biology where his research group is located in the Manchester Institute of Biotechnology Biocentre (MIB: www.mib.ac.uk). He is Director of the Centre of Excellence in Biocatalysis (CoEBio3) (www.coebio3.org) and a Co-Director of SYNBIOCHEM, the BBSRC Synthetic Biology Research Centre. He is also a co-founder of Ingenza (www.ingenza.com). He is a member of the Editorial Board of ChemCatChem and Advanced Synthesis and Catalysis. His research interests are in the area of biocatalysis with particular emphasis on the discovery and development of novel enzyme catalysed reactions for applications in organic synthesis. His group are also interested in the application of directed evolution technologies for the development of biocatalysts with tailored functions
T21 - With Asymmetric Hydrogenation towards a Scalable, Stereoselective Synthesis of Bitopertin
F. HOFFMANN-LA ROCHE AG, Basel, Switzerland
- Schools in Avellino, Italy
- Graduation in 1978 at the University of Naples, Italy, Prof. A. Panunzi
- PhD in 1983 at the ETH/Zürich, Prof. P. Pino
- At Roche Basel since 1984 working in the Catalysis & Process R&D area
- In 1990-91 worked at Roche Nutley (USA) in the Kilolab Area
- Since 1995 Head of the Catalysis Laboratory at the Process R&D Department
- In 2010 and 2013 Winner of Roche’s Technical R&D Green Chemistry Award
- In 2015 promotion to Distinguished Scientist (highest for scientists at Roche)
- In 2015 Senior Industrial Investigator Award of the Swiss Chemical Society
Originally an organometallic chemist, Michelangelo Scalone is a Process R&D chemist with particular experience in homogeneous and heterogeneous catalytic reactions, especially asymmetric reactions (e.g. hydrogenations, carbonylations, cyclizations, cyclopropanations, metathesis etc.) and in the synthesis of chiral homogeneous catalysts. His task is, together with his team, to create short, efficient, reproducible, safe, ecological and economical syntheses with technical potential for new pharmaceutical development compounds. This requires the command of “standard” organic chemistry as well as the rapid employment of diverse catalytic methodologies, their re-shaping in view of large scale application and sometimes the synthesis of new catalysts and ligands. Co-author of 46 patents and 55 papers.
OC09 - Development of Synthesis Strategies to DNA-Encoded Compound Libraries - of a Chemoresistant Sequence, and Micellar Nanoreactors
TU DORTMUND, Dortmund, Germany
Andreas Brunschweiger studied pharmacy at the University of Kiel (Germany), before joining the group of Prof. Christa Müller at the University of Bonn (Germany) to obtain his Ph.D in 2007. After conducting postdoctoral research in the same group in a collaboration project with UCB Pharma to develop small molecule inhibitors for targets associated with neurodegenerative diseases, he joined Prof. Jonathan Hall’s research group at the Institute of Pharmaceutical Sciences of the ETH Zurich in 2010. There, he was involved in the synthesis of labelled microRNAs to study their biological properties, the development of a chemical biology strategy to identify target RNAs of microRNAs, and the design and synthesis of short chemically modified oligonucleotides as microRNA inhibitors. In 2013 he took up his present position as a group leader at the Faculty of Chemistry and Chemical Biology at the TU Dortmund University. His current research interests include the development of new synthesis and encoding strategies that allow for expanding the chemical space of DNA-encoded small molecule screening libraries.
Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
T22 - Collaborative Academic/Industrial Research Under the Umbrella of the NSF Center for Selective C-H Functionalization
EMORY UNIVERSITY, Atlanta, United States
Huw M. L. Davies was born in Aberystwyth, Wales, UK. He received his B. Sc. degree from University College Cardiff, Wales (1977) and his Ph. D degree from the University of East Anglia (1980). After a post-doctoral position at Princeton University (1980-1983), he joined the faculty at Wake Forest University (1883-1995). After being promoted to full professor he moved to the University at Buffalo, the State University of New York (1995-2008) where he held the positions of UB Distinguished Professor and Larkin Professor of Organic Chemistry. In 2008 he moved to Emory University as the Asa Griggs Candler Professor of Chemistry.
Professor Davies’ research emphasizes the development of new enantioselective synthetic methods and their applications in total synthesis and drug discovery. A major current theme of his program is catalytic asymmetric C–H functionalization by means of rhodium-carbene induced C–H insertion. He is currently the Director of the NSF Phase II Center for Chemical Innovation for Selective C-H Functionalization, which brings together 23 faculty members from 15 universities.
Professor Davies is actively involved in the chemical community, having served as the Executive Officer of the 2003 National Organic Symposium, the 2005 Program Chair of the Gordon Conference on Heterocyclic Compounds, the 2005 Chair of the Organic Division of the American Chemical Society, and Co-Organizer of the ACS Organic Division Assistant Professor Symposium at the Fall ACS meeting since 2006. He is an Associate Editor for Chemical Society Reviews and Organic Syntheses. Recent awards include the American Chemical Society Cope Scholar Award (2005), Fellow of the Royal Society of Chemistry (2007), Fellow of the American Chemical Society (2009), Fellow of the American Association for the Advancement of Science (2012), 2013 eEROS Reagent of the Year Award, Fellow of the National Academy of Inventors (2015), and the Alexander von Humboldt Foundation Research Award (2017).
Roundtable discussion: “Enabling Advances in the Science of Synthesis through Industry-Academic collaborations in the 21st Century”
Coffee Break and Exhibition
UNIVERSITY OF ANTWERP, Antwerp, Belgium
EFMC Prize for a Young Medicinal Chemist in Academia
OC10 - Nature-Derived Peptides as Pharmacological Tools to Design Novel Therapeutics
Christian W. GRUBER
MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria
Christian Gruber is research group leader and Associate Professor at the Medical University of Vienna (Austria), and an ARC Future Fellow at The University of Queensland (Australia). He studied Biochemistry at the University of Tübingen (Germany), Molecular Biotechnology at the Queensland University of Technology (Australia), and received a Ph.D. in Molecular Biosciences from The University of Queensland. The research focus of his team is to study biological function, structure-activity relationship and pharmacological mechanism of nature-derived peptides isolated from plants and invertebrates (e.g., peptide hormones, neuropeptides and peptide toxins), and the development of novel peptide therapeutics.
Further information: http://www.meduniwien.ac.at/pharmakologie/ms/
EFMC Prize for a Young Medicinal Chemist in Industry:
OC11 - The Development of non-BET Bromodomain Chemical Probes
GLAXOSMITHKLINE, Stevenage, United Kingdom
Phil Humphreys is a Scientific Leader, GSK Fellow and medicinal chemist in the Epigenetics Discovery Performance Unit in GlaxoSmithKline Stevenage. He studied Biochemistry and Biological Chemistry at the University of Nottingham before completing his organic chemistry PhD. studies under the supervision of Prof. David Hodgson at the University of Oxford in 2007. Phil then completed his postdoctoral studies in the laboratory of Prof. Larry Overman at the University of California, Irvine as a Merck Sharp & Dohme Postdoctoral Research Fellow working on the total synthesis of alkaloid natural products. He began his medicinal chemistry career in 2009, joining the Immune Memory DPU in GSK, Stevenage before transitioning to the Epinova DPU in early 2010 where he has worked since. Phil has led programmes on a variety of targets in the epigenetic space, and has a particular interest in bromodomains as therapeutic targets.
T23 - Strategies towards Increasing the 3-Dimensionality of the Medicinal Chemistry Design Space
Antonia F. STEPAN
PFIZER, Basel, Switzerland
Antonia F. Stepan is a Senior Principal Scientist and Project Team Leader in the Neuroscience and Pain Department at Pfizer. Antonia received her undergraduate degree from the ETH Zurich, Switzerland, and her Ph.D. from the University of Cambridge, UK, under the guidance of Professor Steven V. Ley. After two years of postdoctoral studies with Professor K. C. Nicolaou at the Scripps Institute in La Jolla, California, Antonia joined the Pfizer Medicinal Chemistry Department at the end of 2008. Her research interest focuses on the discovery of novel medicines for the treatment of neurodegenerative diseases. She has co-authored more than 35 peer-reviewed papers, reviews, and patents and was recognized as a ‘Young Investigator in Medicinal Chemistry' by the American Chemical Society in 2015.